is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commerical property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel Plasticity.

Date: May 6, 2003.

Time: 4 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Daniel R. Kenshalo, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5176, MSC 7844, Bethesda, MD 20892, 301–435–1255.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Crandall R01 Review.

Date: May 21, 2003.

Time: 1 p.m. to 4 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Room 4158, Bethesda, MD 20916, (Telephone Conference Call).

Contact Person: Sergei Ruvinov, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4158, MSC 7806, Bethesda, MD 20892, (301) 435–1180, *ruvinser@csr.nih.gov.*

Name of Committee: Molecular, Cellular and Developmental Neuroscience Integrated Review Group, Molecular, Cellular and Developmental Neurosciences 5.

Date: June 4–5, 2003.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: The Fairmont Washington, DC, 2401 M Street, NW., Washington, DC 20037.

Contact Person: Syed Husain, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5216, MSC 7850, Bethesda, MD 20892, (301) 435–1224, *husains@csr.nih.gov.*

Name of Committee: Infectious Diseases and Microbiology Integrated Review Group, Tropical Medicine and Parasitology Study Section.

Date: June 5–6, 2003.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn Georgetown, 2101 Wisconsin Avenue, NW., Washington, DC 20007.

Contact Person: Jean Hickman, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3194, MSC 7808, Bethesda, MD 20892, (301) 435–1146, *hickmanj@csr.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: April 28, 2003.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 03–11070 Filed 5–5–03; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Clinical Center; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of The Board of Scientific Counselors of the Warren Grant Magnuson Clinical Center.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: The Board of Scientific Counselors of the Warren Grant Magnuson Clinical Center Executive Committee.

Date: June 9–10, 2003.

Time: 8 a.m. to 5 p.m.

Agenda: Personal qualifications and performance, and competence of individual investigators.

Place: National Institutes of Health, Building 10, 10 Center Drive, Clinical Center Med Brd Rm 2C116, Bethesda, MD 20892.

Contact Person: David K Henderson, MD, Deputy Director for Clinical Care, Office of the Director, Clinical Center, National Institutes of Health, Building 10, Room 2C146, Bethesda, MD 20892, 301/402–0244.

Dated: April 28, 2003.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 03–11068 Filed 5–05–03; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Co-Exclusive License: Convection Enhanced Drug Delivery for Transforming Growth Factor Alpha (TGFα)

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is a public notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a worldwide co-exclusive license with one other licensee to practice the inventions embodied in: U.S. Patent 5,720,720, issued February 24, 1998, entitled ''Convection-enhanced drug delivery'' (Laske, *et al.*) (U.S. Patent Application Serial No. 08/616,785, filed March 15, 1996) to Kaleidos Pharma, Inc. of Seattle, Washington.

The United States of America is the assignee to the patent rights of these inventions. The contemplated co-exclusive license may be restricted to the fields that include the use of the Convection Enhanced Delivery (CED) technique for therapeutic delivery of the Transforming Growth Factor Alpha (TGFα) family of growth factors, truncated TGFα family of growth factors, truncated TGFα polypeptides and modified TGFα, for treating Parkinson's disease.

DATES: Only written comments and/or applications for a license that are received by the NIH Office of Technology Transfer on or before July 7, 2003 will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Michael Shmilovich, J.D.,A Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435–5019; Facsimile: (301) 402–0220; E-mail: *mish@codon.nih.gov.*

SUPPLEMENTARY INFORMATION: The invention is a method for high-flow microinfusion of drug agents into the brain and other solid tissue structures. The method involves positioning the tip of an infusion catheter within a tissue structure and supplying an agent through the catheter while maintaining a pressure gradient from the tip of the catheter during infusion. Agent delivery

rates of from 0.5 to 15.0 microliter/min have been used experimentally with infusion distances greater than 1 cm from the delivery source. The patent is limited to the method of delivery, and only U.S. rights for the invention were preserved.

The prospective co-exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective co-exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: April 24, 2003.

Steven M. Ferguson,

Acting Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 03–11072 Filed 5–5–03; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

Agency Information Collection Activities: Submission for OMB Review; Comment Request

AGENCY: Federal Emergency Management Agency, Emergency Preparedness and Response Directorate, Department of Homeland Security.

ACTION: Notice and request for comments.

SUMMARY: The Federal Emergency Management Agency (FEMA) is submitting a request for review and approval of a collection of information under the emergency processing procedures in Office of Management and Budget (OMB) regulation 5 CFR 1320.13. FEMA is requesting that this information collection be approved by May 12, 2003. The approval will authorize FEMA to use the collection through November 30, 2003. FEMA plans to follow this emergency request with a request for a 3-year approval. The request will be processed under OMB's normal clearance procedures in accordance with the provisions of OMB regulation 5 CFR 1320.10. To help us with the timely processing of the emergency and normal clearance submissions to OMB, FEMA invites the general public to comment on the proposed collection of information.

SUPPLEMENTARY INFORMATION: The proposed collection of information is for the administration of the Pre-Disaster Mitigation program as authorized under Section 203 of the Robert T. Stafford Disaster Relief and Emergency Assistance Act (Stafford Act), 42 U.S.C. 5133, as amended by section 102 of the Disaster Mitigation Act of 2000 (DMA), Pub. L. 106–390, 114 Stat. 1552. In accordance with the Act, FY 2003 Consolidated Appropriation Resolution, Pub. L. 108–7 authorized $150 million for the Pre-Disaster Mitigation Program.

Collection of Information

Title: Pre-Disaster Mitigation Grant Program (PDM)/eGrants.

Type of Information Collection: Existing collection in use without an OMB control number.

Forms: The following forms are used for PDM grant application and reporting:

SF 424, Application for Federal Assistance;

SF LLL, Disclosure of Lobbying Activities;

FEMA Form 20–10, Financial Status Report;

FEMA Form 20–15, Budget Information—Construction Program;

FEMA Forms 20–16, Summary Sheet for Assurances and Certifications;

FEMA Form 20–16A, Assurances—Nonconstruction Programs;

FEMA Form 20–16B, Assurances—Construction Programs;

FEMA Form 20–16C, Certifications Regarding Lobbying; Debarment, Suspension and other Responsibility Matters; and Drug-Free Workplace Requirements;

FEMA Form 20–17, Outlay Report and Request for Reimbursement;

FEMA Form 20–18, Report of Government Property;

FEM Form 20–19, Report of Unobligated Balance of Federal Funds;

FEMA Form 20–20, Budget Information—Nonconstruction Programs; and,

FEMA Form 76–10A, Obligating Document for Award.

Abstract: This collection is necessary to provide Federal grant assistance to States, local governments and Federally recognized Indian Tribal governments to develop mitigation plans in accordance with Section 322 of the DMA of 2000, to implement pre-disaster mitigation projects that primarily reduces the risks of natural hazards on life and property but may include hazards caused by non-natural forces, and to provide information and technical assistance on cost-effective mitigation activities. In FY 2003, FEMA will make the Pre-Disaster Mitigation Grant application available on-line to States and local governments through a web-based eGrants application process.

Affected Public: State, local and Tribal governments.

Number of Respondents: 1,176. The number of respondents includes 56 States and Territories plus 20 local governments (to include Indian Tribal governments) per State, or 1,120 local governments, Local governments submit their applications to the States to review, coordinate and forward PDM grant applications to FEMA for approval.

Estimated Total Annual Burden Hours: 50,887.

Estimated Cost: The total annual estimated costs to States, Territories, Indian Tribal governments and local governments for the information collection associated with the PDM program is $1,215,182. This cost is determined by multiplying the respondents estimate hourly rate times the estimated total annual burden hours ($23.88 × 50,887 = $1,215,182.)

Comments: Written comments are solicited to (a) evaluate whether the proposed data collection is necessary for the proper performance of the agency, including whether the information shall have practical utility; (b) evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (c) enhance the quality, utility, and clarity of the information to be collected; and (d) minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.*, permitting electronic submission of responses. Submit comments to OMB within 30 days of the date of this notice. To ensure that FEMA is fully aware of any comments or concerns that you share with OMB, please provide us with a copy of your comments. FEMA will continue to accept comments for 60 days from the date of this notice.

OMB Addressee: Interested persons should submit written comments to the Office of Management and Budget, Office of Information and Regulatory Affairs (Attention: Desk Officer for the